ストックスクリーナーアプリを入手
5.92
1.89%
0.11
アフターアワーズ：
5.92
前日終値:
$5.81
開ける：
$5.79
24時間の取引高:
585.91K
Relative Volume:
0.58
時価総額：
$551.83M
収益：
$823.60M
当期純損益:
$-116.00M
株価収益率:
-4.5538
EPS:
-1.3
ネットキャッシュフロー:
$-107.30M
1週間 パフォーマンス:
+4.23%
1か月 パフォーマンス:
-8.64%
6か月 パフォーマンス:
+33.03%
1年 パフォーマンス:
-54.32%
1日の値動き範囲:
$5.625
$5.935
1週間の範囲:
$5.62
$6.15
52週間の値動き範囲:
$3.76
$15.47
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
5.92 | 541.57M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
623.91 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.75 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
694.75 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.04 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.95 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
Myriad Genetics Unveils Commercialization Roadmap For Precise MRD Assay - Nasdaq
Myriad Genetics (MYGN) Outlines Launch Plan for Precise MRD Assa - GuruFocus
Myriad Genetics to launch Precise MRD cancer test in March 2026 - Investing.com
Myriad Genetics Announces Commercial Launch of Precise MRD™ Assay for Enhanced Cancer Detection and Monitoring - Quiver Quantitative
Myriad cancer DNA test detects signals at 1-in-a-million - Stock Titan
Earnings Risk: Whats the outlook for Myriad Genetics Incs sectorBear Alert & Free Verified High Yield Trade Plans - baoquankhu1.vn
Understanding the Setup: (MYGN) and Scalable Risk - Stock Traders Daily
Should I hold or sell Myriad Genetics Inc. nowJuly 2025 Sector Moves & Fast Gaining Stock Reports - mfd.ru
Carrier Screening Market with Insights from Abbott - openPR.com
Myriad Genetics (NASDAQ:MYGN) Downgraded by Zacks Research to Strong Sell - MarketBeat
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm - Finviz
Myriad Genetics (NASDAQ:MYGN) Stock Price Down 6.5%Time to Sell? - MarketBeat
Momentum Shift: Does LARK stock benefit from AI growth2025 Price Momentum & Verified High Yield Trade Plans - baoquankhu1.vn
Myriad Genetics, Inc. (MYGN) Stock Analysis: Uncovering a 36.50% Potential Upside in the Diagnostics Sector - DirectorsTalk Interviews
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights - GlobeNewswire Inc.
Volume Summary: Is now the right time to enter Myriad Genetics IncMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn
What is Myriad Genetics Incs book value per share2025 Market Outlook & Daily Profit Focused Stock Screening - baoquankhu1.vn
MYRIAD GENETICS Q4 2025 Earnings Preview: Recent $MYGN Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Market Review: Can Myriad Genetics Inc. stock double in next 5 yearsOptions Play & Long-Term Safe Investment Ideas - Bộ Nội Vụ
TEM's Collab for Oncology Patient Population Is Gaining Attention - sharewise.com
The Technical Signals Behind (MYGN) That Institutions Follow - Stock Traders Daily
Myriad Genetics forecasts 2026 revenue growth of 6% to $870 million - Investing.com Canada
Myriad Genetics Reports Preliminary Q4 Revenue; Issues 2026 Guidance - Nasdaq
Myriad Genetics announces select preliminary fourth quarter and full year 2025 financial results and introduces full year 2026 financial guidance - marketscreener.com
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance - The Manila Times
Myriad Genetics Announces Select Preliminary Fourth Quarter And Full Year 2025 Financial Results And Introduces Full Year 2026 Financial Guidance - TradingView — Track All Markets
About Us - FinancialContent
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Why Myriad Genetics Inc. stock is in analyst buy zoneJuly 2025 Institutional & Target Return Focused Stock Picks - ulpravda.ru
What Analysts Think Is Shaping The Story For Myriad Genetics (MYGN) Now - Yahoo Finance
Can Myriad Genetics Inc. stock outperform in 2025 bull market2025 Short Interest & Growth-Oriented Investment Plans - ulpravda.ru
Is Myriad Genetics Inc. (MYD) stock a good hedge against inflationJuly 2025 Highlights & Capital Protection Trading Alerts - Улправда
Will Myriad Genetics Inc. stock benefit from infrastructure spending2025 Geopolitical Influence & Verified Trade Idea Suggestions - Улправда
Can Myriad Genetics Inc. (MYD) stock surprise with quarterly resultsQuarterly Investment Review & Consistent Return Strategy Ideas - Улправда
Clinical Laboratory Services Market is expected to reach US$ - openPR.com
Myriad Genetics (NASDAQ:MYGN) Stock Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Is Myriad Genetics Inc a good long term investmentMid Cap Growth Trends & Free Discover Massive Upside Stocks - earlytimes.in
The Truth About Myriad Genetics Inc: Is This DNA Stock a Sleeper Goldmine or Just Overhyped? - AD HOC NEWS
What analysts say about Myriad Genetics Inc stockPrice Gap Trading Strategies & Free Unmatched Market Gains - earlytimes.in
Should Myriad Genetics stock stay in your portfolio right now? - MSN
Myriad Genetics Inc Stock Analysis and ForecastHealthcare Stock Analysis & Small Investment Portfolio Tips - earlytimes.in
Precision Trading with Myriad Genetics Inc. (MYGN) Risk Zones - Stock Traders Daily
Should Myriad Genetics Stock Stay in Your Portfolio Right Now? - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Pancreatic Cancer Market is projected to reach US$ 5.7 billion - openPR.com
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Looking at the Narrative for Myriad Genetics After Price Target Revisions and Growth Concerns - Yahoo Finance
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz
Can Myriad Genetics Inc. stock sustain revenue growth2025 Macro Impact & Low Volatility Stock Recommendations - Улправда
Avoiding Lag: Real-Time Signals in (MYGN) Movement - news.stocktradersdaily.com
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
0.21%
大文字化:
|
ボリューム (24 時間):